Motley Fool Asset Management LLC Invests $1.96 Million in ADMA Biologics Inc $ADMA

Motley Fool Asset Management LLC bought a new position in ADMA Biologics Inc (NASDAQ:ADMA) during the fourth quarter, Holdings Channel reports. The fund bought 107,589 shares of the biotechnology company’s stock, valued at approximately $1,962,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. State Street Corp grew its position in shares of ADMA Biologics by 5.6% in the 2nd quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock worth $219,950,000 after buying an additional 637,727 shares during the period. Westfield Capital Management Co. LP grew its position in shares of ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after buying an additional 1,886,105 shares during the period. Capital Research Global Investors grew its position in shares of ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after buying an additional 3,383,559 shares during the period. Geode Capital Management LLC grew its position in shares of ADMA Biologics by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 5,830,941 shares of the biotechnology company’s stock worth $106,374,000 after buying an additional 17,203 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of ADMA Biologics by 0.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,798,274 shares of the biotechnology company’s stock worth $70,343,000 after buying an additional 35,199 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Jerrold B. Grossman acquired 12,500 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $8.01 per share, with a total value of $100,125.00. Following the transaction, the director owned 513,884 shares of the company’s stock, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 3.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ADMA shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Mizuho reduced their target price on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Raymond James Financial started coverage on shares of ADMA Biologics in a research report on Wednesday. They issued an “outperform” rating and a $21.00 target price on the stock. Finally, Canaccord Genuity Group reduced their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $19.67.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $8.48 on Thursday. ADMA Biologics Inc has a one year low of $7.21 and a one year high of $22.37. The company’s 50-day moving average is $9.21 and its 200 day moving average is $14.26. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 12.47 and a beta of 0.72. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The company had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. During the same period in the prior year, the firm posted $0.11 EPS. ADMA Biologics’s revenue for the quarter was down .3% on a year-over-year basis. Sell-side analysts expect that ADMA Biologics Inc will post 0.84 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.